2012 SurgiMAB BioPharmInsight

SurgiMab > News & Events > News > In the press : “SurgiMab to sign a deal with a French CMO…” > 2012 SurgiMAB BioPharmInsight

18 April 2016 Administrateur SurgiMabLeave a comment0

SurgiMAB to sign a deal with French CMO in two weeks, seeking financing, president says

Previous Post
In the press : “SurgiMab to sign a deal with a French CMO…”

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

SurgiMab will sponsor the next edition of the International Symposium on Fluorescence Guided Surgery, 2-3 Nov 2023 in Amsterdam
SurgiMab will participate to the conference “Optics in the Life Sciences” during the Optica Biophotonics Congress in Vancouver April 23 – 27, 2023

Home . Legal & credits